Phys.org on MSN11d
Revolutionizing Antibody Discovery: MIT’s AI BreakthroughWith this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...
Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...
ScienceAlert on MSN2d
Parkinson's Discovery Suggests We Could Already Have an FDA-Approved TreatmentParkinson's symptoms mainly result from the death or impairment of dopamine-producing neurons in the brain's substantia nigra ...
AMD collaborates with Absci for AI drug discovery advancements ... and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private ...
Aragen, based in Hyderabad, says it will use the funds to boost manufacturing capacity for newer treatment modalities, such ...
a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody-Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback